InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

RECURSION PHARMACEUTICALS, INC.

RXRX Clue Score61
United States Fiscal year ends December CIK 0001601830
$4.36 +10.38% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $4.36 −76.27% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 16 Apr 2021. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2019Revenue2.3Operating income−62.4Net income−61.9EPS, diluted−2.87Fiscal year 2020Revenue4.0 +70.8%Operating income−84.6Net income−87.0EPS, diluted−3.99Fiscal year 2021Revenue10.2 +156.9%Operating income−182.8Net income−186.5EPS, diluted−1.49Fiscal year 2022Revenue39.8 +291.5%Operating income−245.7Net income−239.5EPS, diluted−1.36Fiscal year 2023Revenue44.6 +11.9%Operating income−350.1Net income−328.1EPS, diluted−1.58Fiscal year 2024Revenue58.8 +32.0%Operating income−479.0Net income−463.7EPS, diluted−1.69Fiscal year 2025Revenue74.7 +26.9%Operating income−648.1Net income−644.8EPS, diluted−1.44
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue 2.3 4.0 10.2 39.8 44.6 58.8 74.7
Growth +70.8% +156.9% +291.5% +11.9% +32.0% +26.9%
Operating income −62.4 −84.6 −182.8 −245.7 −350.1 −479.0 −648.1
Net income −61.9 −87.0 −186.5 −239.5 −328.1 −463.7 −644.8
Growth
EPS, diluted −2.87 −3.99 −1.49 −1.36 −1.58 −1.69 −1.44

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2019Operating margin−2,692.6%Net margin−2,668.3%Free cash flow margin−2,628.4%Fiscal year 2020Operating margin−2,135.7%Net margin−2,196.0%Free cash flow margin−1,293.0%Fiscal year 2021Operating margin−1,795.8%Net margin−1,832.2%Free cash flow margin−1,949.4%Fiscal year 2022Operating margin−616.7%Net margin−601.0%Free cash flow margin−302.6%Fiscal year 2023Operating margin−785.3%Net margin−736.0%Free cash flow margin−672.4%Fiscal year 2024Operating margin−814.1%Net margin−788.0%Free cash flow margin−633.7%Fiscal year 2025Operating margin−867.9%Net margin−863.4%Free cash flow margin−506.5%
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating margin −2,692.6% −2,135.7% −1,795.8% −616.7% −785.3% −814.1% −867.9%
Net margin −2,668.3% −2,196.0% −1,832.2% −601.0% −736.0% −788.0% −863.4%
Free cash flow margin −2,628.4% −1,293.0% −1,949.4% −302.6% −672.4% −633.7% −506.5%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2019Operating cash flow−57.0Capital expenditure−3.9Free cash flow−61.0Fiscal year 2020Operating cash flow−45.4Capital expenditure−5.8Free cash flow−51.2Fiscal year 2021Operating cash flow−158.6Capital expenditure−39.8Free cash flow−198.4Fiscal year 2022Operating cash flow−83.5Capital expenditure−37.1Free cash flow−120.6Fiscal year 2023Operating cash flow−287.8Capital expenditure−12.0Free cash flow−299.7Fiscal year 2024Operating cash flow−359.2Capital expenditure−13.7Free cash flow−372.9Fiscal year 2025Operating cash flow−371.8Capital expenditure−6.5Free cash flow−378.3
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −57.0 −45.4 −158.6 −83.5 −287.8 −359.2 −371.8
Capital expenditure −3.9 −5.8 −39.8 −37.1 −12.0 −13.7 −6.5
Free cash flow −61.0 −51.2 −198.4 −120.6 −299.7 −372.9 −378.3
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
CashTotal debt
Fiscal year 2019Cash75.2Shareholders’ equity−124.3Fiscal year 2020Cash262.1Shareholders’ equity−206.3Fiscal year 2021Cash285.1Total debt0.7Net cash (debt)284.4Shareholders’ equity542.9Debt to equity0.00Fiscal year 2022Cash549.9Shareholders’ equity485.8Fiscal year 2023Cash391.6Shareholders’ equity463.4Fiscal year 2024Cash594.4Shareholders’ equity1,034.8Fiscal year 2025Cash743.3Shareholders’ equity1,130.9
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash 75.2 262.1 285.1 549.9 391.6 594.4 743.3
Total debt n/a n/a 0.7 n/a n/a n/a n/a
Net cash (debt) n/a n/a 284.4 n/a n/a n/a n/a
Shareholders’ equity −124.3 −206.3 542.9 485.8 463.4 1,034.8 1,130.9
Debt to equity n/a n/a 0.00 n/a n/a n/a n/a

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2019 31 Dec 2019 FY2020 31 Dec 2020 FY2021† 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025† 31 Dec 2025
Revenue and profit
2.3 4.0 10.2 39.8 44.6 58.8 74.7
Growth +70.8% +156.9% +291.5% +11.9% +32.0% +26.9%
n/a 0.0 0.0 48.3 42.6 45.2 71.0
45.8 63.3 135.3 155.7 241.2 314.4 475.3
19.0 25.3 57.7 81.6 110.8 178.2 176.6
−62.4 −84.6 −182.8 −245.7 −350.1 −479.0 −648.1
Growth
n/a n/a −186.5 −239.5 −332.1 −464.8 −644.9
0.0 0.0 0.0 0.0 −4.1 −1.1 −0.1
−61.9 −87.0 −186.5 −239.5 −328.1 −463.7 −644.8
Growth
Per share
−2.87 −3.99 −1.49 −1.36 −1.58 −1.69 −1.44
−2.87 −3.99 −1.49 −1.36 −1.58 −1.69 −1.44
Growth
21.6 21.8 125.3 175.5 207.9 274.2 447.4
21.6 21.8 125.3 175.5 207.9 274.2 447.4
Growth +1.0% +475.5% +40.0% +18.4% +31.9% +63.2%

† The diluted share count jumps at 2021 and 2025, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Five years in brief

Worked out from the figures above, not from a press release
  • Revenue grew 79.9% a year over five years.
  • Operating margin is up 1,267.8 points on five years ago, at -867.9%.
  • A net loss in 7 of 7 years on file.